Humoral rejection is refractory to conventional high-dose corticosteroid pulse therapy and invariably requires the addition of depleting antibodies, either polyclonal antilymphocyte agents or OKT3.
There has been a great deal of recent work that has used the combination of plasmapheresis and intravenous immunoglobulin (IVIG) to treat humoral rejection. It seems to be an important advance.
The molecular pathways contributing to humoral-mediated allograft rejection are poorly defined. In this study, we assessed the role of the herpesvirus entry mediator/B- and T-lymphocyte attenuator ...
Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic ...
A research study at the University of Chicago has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that ...
A research study at the University of Chicago has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that ...
IN recent months it has become increasingly evident that humoral antibodies as well as cellular immune mechanisms sometimes play an active part in the rejection of human kidney transplants. Several ...
Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants
Amid the debate over which combination of immunosuppressive agents works best in helping patients fight off rejection of their new heart after transplant surgery, a new study led by researchers at the ...
A research study has found that in pregnancy, while the T cell response to a fetus becomes tolerant to allow for successful pregnancy, the part of the immune system that produces antibodies (known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results